Last reviewed · How we verify
Ethamide (ETHOXZOLAMIDE)
Ethamide works by inhibiting the enzyme carbonic anhydrase 2, which helps regulate the balance of acid and base in the body.
Ethamide (ETHOXZOLAMIDE) is a small molecule drug that targets carbonic anhydrase 2, a key enzyme involved in the regulation of acid-base balance in the body. It is classified as an ethoxzolamide and is off-patent, meaning it is no longer protected by patents. The exact indications for which it is approved are unknown, and its commercial status is unclear. Ethamide has a bioavailability of 65% but its half-life is unknown. As a result, its use and safety profile are not well established.
At a glance
| Generic name | ETHOXZOLAMIDE |
|---|---|
| Sponsor | Pfizer |
| Drug class | ethoxzolamide |
| Target | Carbonic anhydrase 1, Carbonic anhydrase 12, Carbonic anhydrase 13 |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
| First approval | 1982 |
Mechanism of action
Think of it like a leaky faucet - carbonic anhydrase 2 helps control how much acid flows into the body's cells. When it's working properly, it helps keep the right balance of acid and base. Ethamide blocks this enzyme, which can help reduce the amount of acid in the body.
Approved indications
Common side effects
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ethamide CI brief — competitive landscape report
- Ethamide updates RSS · CI watch RSS
- Pfizer portfolio CI